Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.

Celularity Inc.

Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and economics. Celularity’s innovative approach to cell therapy harnesses the unique therapeutic potential locked within the postpartum placenta. Through nature’s immunotherapy engine – the placenta – Celularity is leading the next evolution of cellular medicine with placenta-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases. To learn more visit celularity.com.

Dragasac Limited

Sorrento Therapeutics

Starr Insurance Companies

Alumni Ventures

Heritage Group

Human Longevity

Section 32 Celgene

United Therapeutics

Bill Maris

Tony Robbins

We're excited for the future here at Celularity and are off to an invigorating 2024! Net sales expectations and updates can be found in the full release, linked below.

Exciting announcement! The opportunity to manufacture placental-derived biomaterials for distribution by BioCellgraft will bring our exceptional, proven technology to the management of oral healthcare concerns and fill the treatment gap for patients who suffer from soft tissue and hard tissue conditions.

Excited about the future at Celularity!
https://lnkd.in/gmJmRJCP

We're pleased to have had our Chairman, CEO and Founder, Dr. Bob Hariri, featured by Cell & Gene .  Discussion topics included lessons learned in allogeneic cell therapy, advice for allogeneic cell therapy start-ups, the strategy behind the Celularity facility, and more. 
#celltherapy #cellandgenetherapy 
https://lnkd.in/dj2Sr_3c

We’re pleased to announce our exclusive U.S. commercialization agreement with Verséa Health (Verséa Ophthalmics), which will allow us to support eye care professionals as they treat ocular surface diseases and perform certain ocular surgeries. Discover more about the partnership: https://bit.ly/3YcZdOM

Next Wednesday, July 26, our team will present data on Celularity’s proprietary #biomaterials at the International Conference on Biomaterials Science and Tissue Engineering (ICBSTE) in Osaka, Japan.

Presented by Anna Gosiewska, PhD, the data will include three benchtop and clinical case studies for three Celularity human placental-derived advanced biomaterial products. Find out more about the data here: https://bit.ly/3JY4LXS

Check out this interview with our Chairman, CEO and Founder, Dr. Bob Hariri, in the latest issue of Pulse 2.0
https://lnkd.in/ejr2bu6X

Next month, Celularity will present at the 7th International Conference on Orthopedics in Rome. The oral session will share data from a new technology in development for orthopedic applications.
 
Read the full announcement to learn more about the study: https://bit.ly/3NpgMGA

Exciting update: data featured in the journal Cytotherapy demonstrate that CRISPR-mediated tissue factor (TF) gene knock out (TFKO) in allogeneic stromal cells (ASCs) leads to significantly lower TF expression, activity, and thrombotic effects. This #preclinical #data from an edited version of one of our cell therapy candidates signals a feasible pathway to potentially improve the safety of ASC-based #celltherapy.
 
Full details here: https://bit.ly/3qjvHua

Today, we are excited to announce that we have received a $45 million purchase order for Celularity private label Halal-Certified #biomaterial products from Jamjoom Medicine Store.
 
This marks the first purchase order received under our recently announced expansion into the Middle East market, as part of our global market strategy. Read the full announcement: https://bit.ly/426nqXw

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables		210.21K -	5.39M 2,464.09%	9.32M 72.86%	5.81M 37.64%	14.14M 143.44%
accumulated other comprehensive income loss				-414.13M -	9K 100.00%
cash and cash equivalents	24.71K -	917.01K 3,611.53%	54.31M 5,822.64%	37.24M 31.43%	13.97M 62.50%	227K 98.37%
cash and short term investments	24.71K -	917.01K 3,611.53%	54.31M 5,822.64%	37.24M 31.43%	13.97M 62.50%	227K 98.37%
common stock	863 -	275.56M 31,930,910.54%	1K 100.00%	12K 1,100%	15K 25%	19K 26.67%
deferred revenue			4.83M -	2.20M 54.52%	2.27M 3.51%	2.83M 24.68%
deferred revenue non current			7.62M -	1.87M 75.45%	2.22M 18.60%	3.19M 43.58%
deferrred tax liabilities non current			7K -	10K 42.86%	9K 10%
goodwill			123.30M -	123.30M 0%	119.69M 2.93%	7.35M 93.86%
goodwill and intangible assets			248.68M -	246.49M 0.88%	240.69M 2.35%	18.35M 92.38%
intangible assets			125.38M -	123.19M 1.75%	120.99M 1.78%	11.00M 90.91%
inventory			3.85M -	9.55M 148.03%	5.31M 44.41%	5.75M 8.38%
long term debt			27.63M -	28.09M 1.63%	27.98M 0.36%	26.18M 6.46%
long term investments		291M -		-10K -
net debt	125.29K -	-917.01K 831.89%	-23.67M 2,481.11%	-6.10M 74.21%	51.62M 945.71%	43.17M 16.37%
net receivables			6.55M -	5.23M 20.11%	6.97M 33.12%	10.05M 44.21%
other assets
other current assets		92.15K -	873K 847.37%	2K 99.77%	9.78M 488,700%	3.77M 61.47%
other current liabilities	150.56K -	18.88K 87.46%	13.45M 71,133.38%	11.66M 13.31%	16.40M 40.66%	33.10M 101.79%
other liabilities
other non current assets	149.75K -	-405.46K 370.76%	20.09M 5,054.37%	39.77M 97.99%	38.15M 4.07%	26.92M 29.44%
other non current liabilities		10.81M -	900.47M 8,228.04%	258.52M 71.29%	109.86M 57.50%	6.27M 94.29%
othertotal stockholders equity	24.14K -	2.49M 10,204.77%	32.16M 1,193.07%	763.09M 2,272.64%	443.31M 41.91%	882.73M 99.12%
preferred stock				414.13M -	401.07M 3.15%
property plant equipment net			90.08M -	90.63M 0.61%	88.72M 2.11%	78.82M 11.16%
retained earnings	-1.10K -	2.51M 228,868.03%	-563.56M 22,535.97%	-663.68M 17.77%	-645.50M 2.74%	-841.79M 30.41%
short term debt			3.01M -	3.05M 1.43%	37.60M 1,132.48%	17.22M 54.20%
short term investments
tax assets		1.65K -		10K -	9K 10%	9K 0%
tax payables		18.88K -	10.38K 45.02%
total assets	174.46K -	291.61M 167,050.27%	431.01M 47.81%	414.13M 3.92%	401.07M 3.15%	143.89M 64.12%
total current assets	24.71K -	1.01M 3,984.50%	72.16M 7,050.52%	37.24M 48.39%	33.50M 10.04%	19.79M 40.92%
total current liabilities	150.56K -	229.09K 52.17%	26.68M 11,544.57%	26.23M 1.69%	62.09M 136.75%	67.30M 8.39%
total debt	150K -		30.64M -	31.14M 1.61%	65.59M 110.65%	43.40M 33.83%
total investments		291M -		-10K -
total liabilities	150.56K -	11.04M 7,233.93%	962.41M 8,616.21%	314.71M 67.30%	202.16M 35.76%	102.93M 49.09%
total liabilities and stockholders equity	174.46K -	291.61M 167,050.27%	431.01M 47.81%	414.13M 3.92%	401.07M 3.15%	143.89M 64.12%
total non current assets	149.75K -	290.60M 193,954.22%	358.85M 23.49%	376.89M 5.03%	367.56M 2.47%	124.10M 66.24%
total non current liabilities		10.81M -	935.73M 8,554.16%	288.49M 69.17%	140.08M 51.44%	35.63M 74.56%
total stockholders equity	23.90K -	280.56M 1,173,708.70%	-531.40M 289.40%	99.42M 118.71%	198.90M 100.07%	40.96M 79.41%

COM:CELULARITY

Celularity Inc.

Last Close

2.85

22/11 21:00

Market Cap

61.43M

Beta: -

Volume Today

104.87K

Avg: -

Preview